A PHASE III, RANDOMIZED, MULTICENTERIC, CONTROLLED STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF BBILs TYPHOID Vi CAPSULAR POLYSACCHARIDE-TETANUS TOXOID PROTEIN CONJUGATE VACCINE VS REFERENCE VACCINE IN HEALTHY SUBJECTS - Typbar TCV [EXTENSION OF 700207393]
Latest Information Update: 18 Oct 2021
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary) ; Typhoid vaccine Vi-polysaccharide
- Indications Typhoid
- Focus Pharmacodynamics
- Sponsors Bharat Biotech
- 18 Oct 2021 Status changed from recruiting to completed, as per India Clinical Trials Register record.
- 05 Oct 2021 Results from CTRI2014-01-004341 and CTRI2011-08-001957, for follow on monitoring of serum IgG Vi antibody titers at 3, 5, and 7 years after initial vaccination of infants/toddlers, including those who did, or did not, receive a booster vaccination 720 days post primary immunization, published in the Vaccine
- 19 Feb 2014 New trial record